Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.

7 May 2013

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia.

29 Apr 2013

Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

Proteins, unlike diamonds, aren't forever. And when they wear out, they need to be degraded in the cell back into amino acids, where they will be recycled into new proteins.

29 Apr 2013

UH professor wins grant to develop promising therapies for melanoma

A University of Houston engineering professor has won a grant from the Melanoma Research Alliance to help develop one of the most promising therapies for patients with the disease.

29 Apr 2013

MCCIR scientists use video imaging to investigate effectiveness of rituximab in killing cancerous B cells

Scientists from the Manchester Collaborative Centre for Inflammation Research have discovered why a particular cancer drug is so effective at killing cells.

From The University of Manchester 25 Apr 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.

23 Apr 2013

Senesco completes cohort 2 in Phase 1b/2a clinical study of SNS01-T

Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.

23 Apr 2013

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Pharmacyclics, Inc. announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma, (RESONATE) was achieved on April 3, 2013.

23 Apr 2013

Advances in treatment have improved the chances of survival for young patients with cancer

Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.

22 Apr 2013

New chemical compound offers a promising step for creating potential anti-cancer agents

Scientists at the Walter and Eliza Hall Institute and their collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients.

22 Apr 2013

Shc plays key role in activating and controlling Erk

A protein which is intimately involved in cancer-promoting cell signaling also keeps a key component of the signaling pathway tied down and inactive, a team led by scientists from The University of Texas MD Anderson Cancer Center reports this week in Nature Structural Molecular Biology.

20 Apr 2013

SCCA pioneers new transplant procedures to reduce need for matching bone marrow donors

Patients from ethnic minority and mixed-racial backgrounds are less likely to receive a lifesaving bone marrow transplant than Caucasian patients with the same disease due to lack of matching donors, according to the National Marrow Donor Program.

19 Apr 2013

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.

18 Apr 2013

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results.

18 Apr 2013

FDA grants Fast Track designation to Elorac's naloxone topical lotion

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the U.S. Food and Drug Administration has granted Fast Track designation to the Company's naloxone topical lotion for the relief of pruritus in patients with cutaneous T-cell lymphoma.

15 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

MD Anderson scientists demonstrate new way to restore tumor suppression

Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.

10 Apr 2013

Patients exposed to chest radiation are more likely to die after heart surgery

Patients who have open heart surgery for heart disease caused by radiation cancer treatment are nearly twice as likely to die in the years following their surgery compared to similar patients who did not undergo radiation treatment, according to new research from Cleveland Clinic published today in the American Heart Association journal Circulation.

9 Apr 2013

American Society of Hematology announces first recipients of ASH Bridge Grants

The American Society of Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health.

9 Apr 2013

Lymphoma News and Research

Further Reading

Janssen enrolls patients in expanded access program for mantle cell lymphoma

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

UH professor wins grant to develop promising therapies for melanoma

MCCIR scientists use video imaging to investigate effectiveness of rituximab in killing cancerous B cells

Unavoidable damage to heart and lungs can be limited by using CVD drug

Senesco completes cohort 2 in Phase 1b/2a clinical study of SNS01-T

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Advances in treatment have improved the chances of survival for young patients with cancer

New chemical compound offers a promising step for creating potential anti-cancer agents

Shc plays key role in activating and controlling Erk

SCCA pioneers new transplant procedures to reduce need for matching bone marrow donors

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

FDA grants Fast Track designation to Elorac's naloxone topical lotion

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

MD Anderson scientists demonstrate new way to restore tumor suppression

Patients exposed to chest radiation are more likely to die after heart surgery

American Society of Hematology announces first recipients of ASH Bridge Grants

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News